Loading…
US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population
To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patien...
Saved in:
Published in: | Korean journal of radiology 2019, 20(12), , pp.1653-1661 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613 |
---|---|
cites | cdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613 |
container_end_page | 1661 |
container_issue | 12 |
container_start_page | 1653 |
container_title | Korean journal of radiology |
container_volume | 20 |
creator | Lim, Hyun Kyung Cho, Se Jin Baek, Jung Hwan Lee, Kang Dae Son, Chang Woo Son, Jung Min Baek, Seon Mi |
description | To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population.
Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications.
Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths.
Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery. |
doi_str_mv | 10.3348/kjr.2019.0192 |
format | article |
fullrecord | <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_6291565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2328751485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</originalsourceid><addsrcrecordid>eNpdkk1PGzEYhC3UqqS0R67IUi_tYYO_dmP3gBQhSpFSFYVwtrz-ACcbO9i7rdJfX4dQRDlY78GPx57xAHCM0ZhSxk9XyzQmCItxWeQAjAhCdcUpRW_ACBMiqkYQcQje57xEiAjE2TtwSDGvGa7pCPy5vakuB2-sgXNlfHTJPgw26C2ctp3qfQzQxQRn8Xc193kFr9XGd51KW7i436boDfzhdYpaJe1DXKuv8MI5r1URUMHAG-Vsv4U-QAVnKt1ZeB03w174A3jrVJftx6d5BG6_XSzOv1ezn5dX59NZpRkTfeWQVbpthNFaG4FMU7xZopnixjrGjCCE01aQpnWm4caZVteIUWEmpqaiwfQIfNnrhuTkSnsZlX-cd1GukpzOF1eyIQLXTV3Ysz27Gdq1NdqGPqlObpJfF8-PJ__fCf6-6PySJWVKMC0Cn58EUixB5l6ufda2RBZsHLIsFJ_UmPHdXZ9eocs4pFCikGRCOKFYTEihqj1VUs45Wff8GIzkrgGyNEDuGiB3DSj8yUsHz_S_L6d_AdQJreE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728231972</pqid></control><display><type>article</type><title>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Lim, Hyun Kyung ; Cho, Se Jin ; Baek, Jung Hwan ; Lee, Kang Dae ; Son, Chang Woo ; Son, Jung Min ; Baek, Seon Mi</creator><creatorcontrib>Lim, Hyun Kyung ; Cho, Se Jin ; Baek, Jung Hwan ; Lee, Kang Dae ; Son, Chang Woo ; Son, Jung Min ; Baek, Seon Mi</creatorcontrib><description>To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population.
Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications.
Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths.
Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.</description><identifier>ISSN: 1229-6929</identifier><identifier>EISSN: 2005-8330</identifier><identifier>DOI: 10.3348/kjr.2019.0192</identifier><identifier>PMID: 31854153</identifier><language>eng</language><publisher>Korea (South): The Korean Society of Radiology</publisher><subject>Ablation ; Biopsy ; Electrodes ; Laboratories ; Local anesthesia ; Metastasis ; Patients ; Surgery ; Thyroid ; Thyroid cancer ; Tumors ; Ultrasonic imaging ; 방사선과학</subject><ispartof>Korean Journal of Radiology, 2019, 20(12), , pp.1653-1661</ispartof><rights>Copyright © 2019 The Korean Society of Radiology.</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2019 The Korean Society of Radiology 2019 The Korean Society of Radiology</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</citedby><cites>FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</cites><orcidid>0000-0001-6450-7554 ; 0000-0001-8075-0730 ; 0000-0003-2319-3135</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2728231972/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2728231972?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31854153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002531483$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Hyun Kyung</creatorcontrib><creatorcontrib>Cho, Se Jin</creatorcontrib><creatorcontrib>Baek, Jung Hwan</creatorcontrib><creatorcontrib>Lee, Kang Dae</creatorcontrib><creatorcontrib>Son, Chang Woo</creatorcontrib><creatorcontrib>Son, Jung Min</creatorcontrib><creatorcontrib>Baek, Seon Mi</creatorcontrib><title>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</title><title>Korean journal of radiology</title><addtitle>Korean J Radiol</addtitle><description>To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population.
Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications.
Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths.
Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.</description><subject>Ablation</subject><subject>Biopsy</subject><subject>Electrodes</subject><subject>Laboratories</subject><subject>Local anesthesia</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Surgery</subject><subject>Thyroid</subject><subject>Thyroid cancer</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><subject>방사선과학</subject><issn>1229-6929</issn><issn>2005-8330</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkk1PGzEYhC3UqqS0R67IUi_tYYO_dmP3gBQhSpFSFYVwtrz-ACcbO9i7rdJfX4dQRDlY78GPx57xAHCM0ZhSxk9XyzQmCItxWeQAjAhCdcUpRW_ACBMiqkYQcQje57xEiAjE2TtwSDGvGa7pCPy5vakuB2-sgXNlfHTJPgw26C2ctp3qfQzQxQRn8Xc193kFr9XGd51KW7i436boDfzhdYpaJe1DXKuv8MI5r1URUMHAG-Vsv4U-QAVnKt1ZeB03w174A3jrVJftx6d5BG6_XSzOv1ezn5dX59NZpRkTfeWQVbpthNFaG4FMU7xZopnixjrGjCCE01aQpnWm4caZVteIUWEmpqaiwfQIfNnrhuTkSnsZlX-cd1GukpzOF1eyIQLXTV3Ysz27Gdq1NdqGPqlObpJfF8-PJ__fCf6-6PySJWVKMC0Cn58EUixB5l6ufda2RBZsHLIsFJ_UmPHdXZ9eocs4pFCikGRCOKFYTEihqj1VUs45Wff8GIzkrgGyNEDuGiB3DSj8yUsHz_S_L6d_AdQJreE</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Lim, Hyun Kyung</creator><creator>Cho, Se Jin</creator><creator>Baek, Jung Hwan</creator><creator>Lee, Kang Dae</creator><creator>Son, Chang Woo</creator><creator>Son, Jung Min</creator><creator>Baek, Seon Mi</creator><general>The Korean Society of Radiology</general><general>대한영상의학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0001-6450-7554</orcidid><orcidid>https://orcid.org/0000-0001-8075-0730</orcidid><orcidid>https://orcid.org/0000-0003-2319-3135</orcidid></search><sort><creationdate>20191201</creationdate><title>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</title><author>Lim, Hyun Kyung ; Cho, Se Jin ; Baek, Jung Hwan ; Lee, Kang Dae ; Son, Chang Woo ; Son, Jung Min ; Baek, Seon Mi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ablation</topic><topic>Biopsy</topic><topic>Electrodes</topic><topic>Laboratories</topic><topic>Local anesthesia</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Surgery</topic><topic>Thyroid</topic><topic>Thyroid cancer</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><topic>방사선과학</topic><toplevel>online_resources</toplevel><creatorcontrib>Lim, Hyun Kyung</creatorcontrib><creatorcontrib>Cho, Se Jin</creatorcontrib><creatorcontrib>Baek, Jung Hwan</creatorcontrib><creatorcontrib>Lee, Kang Dae</creatorcontrib><creatorcontrib>Son, Chang Woo</creatorcontrib><creatorcontrib>Son, Jung Min</creatorcontrib><creatorcontrib>Baek, Seon Mi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Korean journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Hyun Kyung</au><au>Cho, Se Jin</au><au>Baek, Jung Hwan</au><au>Lee, Kang Dae</au><au>Son, Chang Woo</au><au>Son, Jung Min</au><au>Baek, Seon Mi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</atitle><jtitle>Korean journal of radiology</jtitle><addtitle>Korean J Radiol</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>20</volume><issue>12</issue><spage>1653</spage><epage>1661</epage><pages>1653-1661</pages><issn>1229-6929</issn><eissn>2005-8330</eissn><abstract>To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population.
Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications.
Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths.
Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.</abstract><cop>Korea (South)</cop><pub>The Korean Society of Radiology</pub><pmid>31854153</pmid><doi>10.3348/kjr.2019.0192</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6450-7554</orcidid><orcidid>https://orcid.org/0000-0001-8075-0730</orcidid><orcidid>https://orcid.org/0000-0003-2319-3135</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1229-6929 |
ispartof | Korean Journal of Radiology, 2019, 20(12), , pp.1653-1661 |
issn | 1229-6929 2005-8330 |
language | eng |
recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_6291565 |
source | Publicly Available Content Database; PubMed Central(OpenAccess) |
subjects | Ablation Biopsy Electrodes Laboratories Local anesthesia Metastasis Patients Surgery Thyroid Thyroid cancer Tumors Ultrasonic imaging 방사선과학 |
title | US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T00%3A15%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=US-Guided%20Radiofrequency%20Ablation%20for%20Low-Risk%20Papillary%20Thyroid%20Microcarcinoma:%20Efficacy%20and%20Safety%20in%20a%20Large%20Population&rft.jtitle=Korean%20journal%20of%20radiology&rft.au=Lim,%20Hyun%20Kyung&rft.date=2019-12-01&rft.volume=20&rft.issue=12&rft.spage=1653&rft.epage=1661&rft.pages=1653-1661&rft.issn=1229-6929&rft.eissn=2005-8330&rft_id=info:doi/10.3348/kjr.2019.0192&rft_dat=%3Cproquest_nrf_k%3E2328751485%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2728231972&rft_id=info:pmid/31854153&rfr_iscdi=true |